Interleukin-1 (IL-1) consists of two distinct forms (IL-1α and IL-1β) and is a master cytokine of local and systemic inflammation (Dinarello et al., 2012). Primarily produced by monocytes, macrophages, and dendritic cells (DCs) in response to stimulation, IL-1β is involved in a variety of biological activities such as cell proliferation, differentiation, and apoptosis through its binding to functional IL-1 receptor I (IL-1RI) expressed on virtually all cells. Thus, IL-1β plays a role as a critical pathogenic mediator of many autoinflammatory, autoimmune, infectious, and degenerative diseases (Dinarello, 2011).

In human T-cell immunity, IL-1β has been identified as an essential cytokine with a role similar to that played by IL-6 in mice for Th17 differentiation, and is also important for expansion, in vivo survival, and effector function of IL-17-producing T cells (Acosta-Rodriguez et al., 2007; Lee et al., 2010). More recently, the importance of IL-1 signaling has been also emphasized in murine Th17 cells. Even though TGF-β and IL-6 are sufficient for murine Th17 differentiation, the IL-1RI knockout (KO) mouse is resistant to experimental autoimmune encephalomyelitis due to a failure to generate Th17 cells (Sutton et al., 2006; Chung et al., 2009). Further, IL-1β and IL-23 along with IL-6 are critical for generation of highly pathogenic Th17 cells in an autoimmune mouse model (Lee et al., 2012; Ronchi et al., 2016). Recent studies have demonstrated that IL-1β functions as a proinflammatory regulator of pathogenic human Th17 cells, which concomitantly produce IFN-γ and GM-CSF (Zielinski et al., 2012). Due to its potent effect as a proinflammatory cytokine, the biological activity of IL-1β is tightly regulated at multiple levels by diverse mechanisms including receptor antagonism through production of a decoy receptor and soluble forms of signaling receptors or accessory proteins (Garlanda et al., 2013a).

The IL-1R signaling complex includes the functional IL-1RI subunit and a signaling subunit, interleukin-1 receptor accessory protein (IL-1RAcP). Dimerization of the IL-1R1 and IL-1RAcP cytoplasmic Toll/IL-1R (TIR) domains initiates a signaling cascade through recruitment of adapter proteins (Garlanda et al., 2013b). The decoy IL-1RII has a short cytoplasmic tail lacking the signal-transducing TIR domain and acts as a molecular trap, capturing IL-1 with high-affinity and exerting a dominant-negative effect (Shirakawa et al., 1987). In contrast to ubiquitously expressed IL-1RI, the expression of IL-1RII is restricted to cells including monocytes, neutrophils, and B cells (Martin et al., 2017; Colotta et al., 1996; Colotta et al., 1993; McMahan et al., 1991). In addition, it was recently demonstrated that human-activated Treg cells and follicular regulatory T (T_fr) cells upregulate IL-1RII to attenuate their IL-1-dependent responses (Tran et al., 2009; Ritvo et al., 2017), suggesting a physiological significance for IL-1RII expression in immune regulation.

The physiological relevance of IL-1RII expression was investigated in autoimmune arthritis animal models using an IL-1RII conditional KO mouse. Deficiency of IL-1RII was found to exacerbate autoimmune arthritis by inhibiting IL-1 signaling in innate cells, such as macrophages and neutrophils (Martin et al., 2017; Shimizu et al., 2015). Our previous study showed that IL-1RII mRNA expression is markedly higher in IL-1RI⁺ memory CD4⁺ T cells compared to IL-1RI^- memory CD4⁺ T cells. Further, the negative regulatory role of IL-1RII was further evidenced by the significant augmentation of IL-17 production by IL-1RI⁺ memory CD4⁺ T cells in response to IL-1β and TCR stimulation after treatment with neutralizing IL-1RII antibody (Lee et al., 2010). Given its preferential expression on IL-17-producing IL-1RI⁺ CD4⁺ T cells as well as Tregs, IL-1RII has been suggested to play a pivotal role in maintaining the balance between Th17 and Treg cells. These cells are reciprocally interconnected in their development pathways and conversion between the two subsets is critical for pathogenesis and resolution of many inflammatory disorders (Zielinski et al., 2012; Basu et al., 2015; Gagliani et al., 2015). However, little is known about the molecular mechanism underlying IL-1RII expression by CD4⁺ T cells and its contribution to modulation of Th17 responses in humans.

Here, we provide novel insight into the immune regulatory role of decoy IL-1RII expressed on human CD4⁺ T cells by exploring its molecular mechanisms of action and analyzing its effect on Th17 responses. TCR stimulation potently induces functional IL-1RI on memory CD4⁺ T cells and a subset of IL-1RI⁺ CD4 T cells co-express decoy IL-1RII, conferring limited responsiveness to IL-1β. IL-RII expression is mediated through binding of a cooperative complex of the transcription factors NFAT and Foxp3 to its promoter. Differential expression of IL-1RI and IL-RII on activated CD4⁺ T cells defines unique immunological features via modulation of IL-1 β responsiveness. Of note, de novo expression of IL-1RI is aberrantly higher in synovial CD4⁺ T cells from RA patients, but TCR-mediated induction of IL-1RII expression is impaired compared to peripheral CD4⁺ T cells from RA patients or healthy controls. These findings underscore the regulatory role of decoy IL-1RII on IL-1β-mediated IL-1R signaling affecting Th17 responses and contributing to pathogenesis of Th17-related disorders.

Th17 cells are a unique subset of CD4⁺ effector T cells that elicit protective immune responses against extracellular bacterial and fungal pathogens (Gaffen, 2009). Th17 cells have been also implicated in the pathogenesis of many autoimmune disorders (Lee et al., 2012; Tabarkiewicz et al., 2015). Unlike conventional Th1 and Th2 cells, Th17 cells exhibit a substantial degree of instability, heterogeneity, and plasticity (Stadhouders et al., 2018). Many molecular mediators are closely involved in regulating plasticity of Th17 cells (Lee et al., 2012; Wang et al., 2015; Ichiyama et al., 2016; Stockinger and Omenetti, 2017). Among these, cytokines are critical determinants in the fate of Th17 cells. TGF-β and IL-6 give rise to nonpathogenic or beneficial Th17 cells, whereas IL-1β, IL-6 and IL-23 are involved in generation of pathogenic Th17 cells (Lee et al., 2012). Further, cell-fate mapping mouse models demonstrate that pathogenic Th17 cells can further convert into Th1 cells producing IFN-γ, but not IL-17 (ex-Th17 Th1 cells), in an IL-23-dependent manner (Hirota et al., 2011), whereas TGF-β is critical for transdifferentiation of Th17 cells into Treg cells (ex-Th17 Treg cells) during the resolution of inflammation or in the cancer microenvironment (Gagliani et al., 2015; Downs-Canner et al., 2017).

IL-1β is an essential cytokine for Th17 biology in humans that boosts Th17 production, induces pathogenic Th17 cells, and impairs the Th17-Treg balance (Basu et al., 2015). Activities of IL-1 are tightly controlled at different levels due to its potent proinflammatory effects. IL-1 receptor antagonist (IL-1Ra) and IL-1RII are negative regulators of the IL-1 system. IL-1Ra binds functional IL-1RI with no recruitment of IL-1RAcP, resulting in the repression of IL-1 binding in a competitive manner, whereas the decoy receptor, IL-1RII cannot transduce the signal initialized by the IL-1RI and IL-1Ra complex (Schlüter et al., 2018). We previously reported that the expression of IL-1RI and IL-1RII on CD4⁺ T cells is dynamically regulated in response to environmental factors such as TCR or cytokine stimulation, and such regulation influences Th17 cell responses (Lee et al., 2010). Furthermore, IL-1RII mRNA is expressed at a higher level in IL-1RI⁺CD4⁺ T cells than in IL-1RI^-CD4⁺ T cells and blockade by IL-1RII leads to reduced IL-17 production (Lee et al., 2010). However, the mechanism modulating IL-1RII expression and its role during the immune response remains unclear.

The expression of IL-1 and IL-1RII is tightly restricted under steady-state conditions, but is upregulated during inflammation (Schlüter et al., 2018). In contrast to IL-1RI, which is ubiquitously expressed at least at low levels, IL-1RII expression is confined to certain cell types, including monocytes, macrophages, some T cells in humans and microglial cells, osteoclasts and neutrophils in mice. Early studies showed that anti-inflammatory signals such as IL-4 and IL-13, as well as dexamethasone stimulate IL-1RII expression by monocytes and macrophages, suggesting its contribution to the anti-inflammatory effect (Colotta et al., 1996; Colotta et al., 1993). IL-1RII can be co-expressed with IL-1RI on the cell surface, albeit at a low copy number, and counterpoises the system by secluding IL-1 and IL-1RAcP from the neighboring signaling receptor IL-1RI (Colotta et al., 1993; Neumann et al., 2000). A recent study demonstrated that the cytosolic form of IL-1RII, expressed in certain types of cells, interacts with pro-IL-1α preventing cleavage and its calpain-dependent maturation and influences necrosis-induced sterile inflammation (Zheng et al., 2013). In a mouse model, IL-1RII deficiency on neutrophils and macrophages was found to aggravate K/BxN serum transfer-induced arthritis and collagen-induced arthritis by inhibiting IL-1 signals (Martin et al., 2017; Shimizu et al., 2015). However, the role of IL-RII on T cells remains to be understood.

We found that TCR-mediated induction of IL-1RI kinetically precedes IL-1RII expression by 12–24 hr and the induction of IL-1RII is predominantly observed in IL-1RI-expressing cells (Figure 2C and D). This suggests cis-regulation by IL-1RII involves its competitive binding to IL-1 and IL-1RAcP on CD4⁺ T cells under inflammatory conditions. Furthermore, treatment with IL-1β, but not other cytokines, further increased the expression of IL-1RII in TCR-stimulated CD4⁺ memory T cells, supporting the idea that there is a negative feedback loop of IL-1 signaling in CD4⁺ T cells (Figure 2—figure supplement 2B).

Of note, IL-1RII expression on memory CD4⁺ T cells was found to correlate with the dose of anti-CD3 mAb used for stimulation, whereas IL-1RI expression was significantly increased following weak anti-CD3 stimulation (100 ng/ml) (Figure 2E). Purvis et al., 2010 demonstrated that low-strength stimulation of human CD4⁺ T cells in a Th17-polarizing cytokine milieu strongly favors Th17 responses. They proposed that low Ca²⁺ signaling in CD4⁺ T cells under low-strength stimulation is preferential for the increase in binding of NFAT to the proximal region of the IL-17 promoter in CD4⁺ T cells, thereby enhancing IL-17 production. It should be noted that this enhancement of Th17 responses is observed only under treatment with Th17-polarizing cytokine such as IL-1β, IL-23, and TGF-β, suggesting a possible role of these cytokines in modulating IL-17 production (Purvis et al., 2010). Our finding may give another explanation as to why low-strength TCR stimulation favors Th17 responses in human CD4⁺ T cells, in that weak induction of IL-1RII leads to elevated IL-1β signaling, which causes increased RORγt activity and IL-17 production. Thus, we suggest that high-strength stimulation induces robust expression of IL-1RII on memory CD4⁺ T cells expressing IL-1RI and suppresses excessive IL-17 production via limiting IL-1β responsiveness (Figure 2F).

Considering the preferential expression of IL-1RII by TCR-induced Foxp3⁺ T cells (Figure 3; Tran et al., 2009; Mercer et al., 2010), it is reasonable to assume that Treg-related TFs are involved in IL-1RII gene expression. Foxp3 forms a multiprotein complex with many protein partners related to the regulation of transcription (Rudra et al., 2012). Among these Foxp3 partners, NFAT plays a key role in regulation of major Treg-related molecules such as CTLA-4, IL-2, and CD25 via direct binding of the NFAT/FOXP3 complex to the promotors of these genes (Wu et al., 2006; Hermann-Kleiter and Baier, 2010). Our findings allow the addition of IL-1RII to this list of genes. In vitro assays using the CsA, a drug targeting NFAT, show selective inhibition of IL-1RII expression on activating IL-1RI⁺ CD4⁺ T cells (Figure 4B). Furthermore, a VIVIT peptide derived from the calcineurin-NFAT-binding motif, PxIxIT, also significantly represses IL-1RII mRNA and protein expression (Figure 4C and D). Repression of NFAT activation by the VIVIT peptide is attributable to inhibition of NFAT binding to calcineurin affecting NFAT-dependent gene expression without affecting calcineurin phosphatase activity (Aramburu et al., 1998; Aramburu et al., 1999). On the contrary, enhanced induction of Foxp3 following treatment with 1,25(OH)two vitamin D3 was found to primarily augment the expression of IL-1RII and resultantly, the ratio of IL-1RII⁺ to IL-1RI⁺ activating CD4⁺ T cells was significantly increased (Figure 4H). This implies that 1,25(OH)two vitamin D3 causes limited IL-1β responsiveness.

An intriguing finding in the present study is that IL-1RII expression is cooperatively controlled by NFAT and Foxp3 in memory CD4⁺ T cells upon TCR stimulation (Figure 5B and C). The crystal structure analysis of the NFAT/FOXP3 complex revealed that the Wing1 domain, specifically amino acids 399–401 from FOXP3, physically interacts with the NFAT protein (Wu et al., 2006; Bandukwala et al., 2011). Based on this finding, Lozano et al., 2015 developed an inhibitory peptide encompassing the Wing1 domain, FOXP3 393–403, which specifically interferes with the NFAT/FOXP3 interaction, without affecting the capacity of NFAT to bind DNA. This peptide inhibits Treg activity via suppression of T-cell conversion into inducible Tregs and enhancement of T cell proliferation. FOXP3 393–403, originally developed for murine Tregs, also has a similar inhibitory effect on the interaction of human NFAT/FOXP3 (Lozano et al., 2015). Our data show that IL-1RII induction on activating IL-1RI⁺ CD4⁺ T cells was significantly reduced by FOXP3 393–403 to a degree comparable to the inhibition of CD25 expression (Figure 5A and C).

These findings were corroborated by our luciferase reporter and ChIP assays (Figure 5D and F). Comparative analysis of DNA sequences using Vista tools revealed that the IL-1RII gene has one small CNS region (−1309 to −1203) in its promoter. Of note, potentially one Foxp3 and two consecutive NFAT binding elements are closely located at positions −1236 to −1230 and −1209 to −1188, respectively, near the CNS region (Figure 5—figure supplement 1). The results of the IL-1RII promoter assay using Foxp3-overexpressing Jurkat T cells suggest that the binding of TFs, probably the NFAT/FOXP3 complex, in the CNS region is involved in increasing IL-1RII promoter activity. Transfection of truncated pGL4/IL-1RII plasmids without the CNS region and of a plasmid with mutated NFAT-binding sequences in the CNS region led to a significant reduction the promoter activity (Figure 5D). Furthermore, it has been demonstrated that in the IL2 promoter, the cooperative interaction between NFAT and Foxp3 involves direct protein–protein contacts between the DNA-binding domains of these transcription factors, at least some of which occur on composite DNA elements (ARRE sequences) with adjacent binding sites for the two transcription factors (Wu et al., 2006; Bandukwala et al., 2011; Hu et al., 2007). However, our ChIP data suggests that although the cooperative interaction between NFAT and Foxp3 is important for induction of IL-1RII, their major DNA-binding domains are located separately in the IL-1RII promoter (Figure 5D–F). This implies a more complex interaction occurs, possibly including tripartite partners and/or 3D looping of the genome. Furthermore, unlike the CD25 gene, there are no ARREs in the CNS region of IL-1RII promoter (Wu et al., 2006).

There are only a few studies describing IL-1RII expression on T cells. IL-1RII is preferentially expressed on TCR-stimulated Treg cells and thus, is a useful selective surface marker of activated human Treg cells (Tran et al., 2009; Mercer et al., 2010). Of interest, we found that IL-1RII expression is also induced by Treg-depleted memory CD4⁺ T cells, suggesting that IL-1RII expression is not strictly limited to activated Tregs. Sakaguchi and colleagues have suggested that FoxP3⁺CD4⁺ T cells consist of three distinct subsets: CD45RA⁺FoxP3^low (naive Treg), CD45RA^-FoxP3^high (effector Treg), and CD45RA^-FoxP3^low (Foxp3-expressing non-Tregs) CD4⁺ T cells. Of these, the CD45RA^-FoxP3^lowCD4⁺ T cell subset contains cells with Th17 potential (Miyara et al., 2009). Considering chemokine receptor and cytokine profiles of IL-1RI⁺CD4⁺ T cells (Figure 3C and D), it is possible that IL-1RI may be predominantly induced on the CD45RA^-FoxP3^lowCD4⁺ T-cell subset. Interestingly, IL-1RI also maintained significantly higher expression on activated human Foxp3⁺ Tregs compared to other T cell subsets despite its important role for Th17 responses (Tran et al., 2009; Mercer et al., 2010). Since Foxp3 is generally induced by TCR stimulation even on Treg-depleted conventional CD4⁺ T cells with Smad3 and NFAT dependent manner (Figure 3—figure supplement 3), strong TCR stimulation results in preferential expression of IL-RII, which limits IL-1β responsiveness and resultantly, reduces Th17 responses. In addition to the fact that the differentiation of Th17 and Treg cells is closely related (Zhou et al., 2008), both cells display instability and plasticity during immune responses; Foxp3⁺ Treg cells can be converted into IL-17-producing cells in certain inflammatory environments and may potentially contribute to pathogenesis of autoimmune diseases, whereas Th17 cells transdifferentiate into Treg cells during resolution of inflammation (Gagliani et al., 2015; Obermajer et al., 2014). Several studies suggest that some Th17 cells act like Tregs and this unique subset of Th17 cells are increased in tumor-bearing mice, human cancer patients (Gagliani et al., 2015; Downs-Canner et al., 2017; Krummey et al., 2014; Thibaudin et al., 2016; Jung et al., 2017), and during several inflammatory diseases. In our study, IL-1RI⁺IL-1RII⁺ cells were found to be similar in phenotype to Treg cells with relatively high expression of CD39, CD73, and CTLA-4 following TCR stimulation (Figures 3B and 6D). Because of their phenotype and potential modulatory function via CTLA-4 and IL-1RII, IL-1RI⁺IL-1RII⁺ cells may act as pivotal regulators of the Th17-cell-mediated inflammatory environment. Thus, the function and homeostatic capacity of IL-1RI⁺IL-1RII⁺ cells require further investigation.

Rheumatoid arthritis is a prototype autoimmune disease characterized by chronic inflammation of the joint synovial membrane (McInnes and O'Dell, 2010; McInnes and Schett, 2011). The disturbed Th17/Treg balance contributes to RA pathogenesis due to the strong pro-inflammatory response of preponderant Th17 cells and impaired Treg cells lacking immunomodulatory capacity, partly due to the cytokine circumstance (Niu et al., 2012; Wang et al., 2012; Noack and Miossec, 2014; Nie et al., 2013). The interesting observation in this study was diminished TCR-mediated induction of IL-1RII, and not IL-1RI, on memory CD4⁺ T cells from RA patients compared to the peripheral counterpart from healthy controls (Figure 7D), causing a significantly reduced ratio of IL-1RI⁺IL-1RII⁺ to IL-1RI⁺IL-1RII^- memory CD4⁺ T cells (Figure 7E). Of note, blocking of IL-1RII on memory CD4⁺ T cells of HCs led to increased IL-1β-mediated induction of IL-17 at a level comparable to that of RA patients (Figure 7F). Given the elevated level of IL-1β in RA synovial fluid and an important role of Th17 responses in RA pathogenesis (Kim et al., 2016; Kay and Calabrese, 2004), impaired induction of IL-1RII may be associated with modulation of IL-17 production in CD4⁺ T cells of RA patients under chronic autoreactive situations.

In summary, the current study provides new insight into the immune regulatory role of the decoy receptor, IL-1RII, expressed by human CD4⁺ T cells in response to TCR stimulation. Here, we investigated the molecular mechanisms underlying IL-1RII expression and analyzing its influence on Th17 responses and consequentially, the Th17/Treg balance. IL-RII expression is mediated molecularly by a cooperative complex of the NFAT and Foxp3 TFs. Further, differential expression of IL-1RI and IL-RII on activated CD4⁺ T cells imparts unique immunological features to these cells via modulation of IL-1β responsiveness. Together, these findings increase understanding of the modulatory mechanisms controlling the Th17 response, and of IL-1β-mediated IL-1R signaling and its contribution to the pathogenesis of autoimmune diseases such as RA.

All data generated or analysed during this study are included in the manuscript and supporting files.

1. 1. Acosta-Rodriguez EV
   2. Napolitani G
   3. Lanzavecchia A
   4. Sallusto F

   (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells

   Nature Immunology 8:942–949.

   https://doi.org/10.1038/ni1496

   • PubMed
   • Google Scholar
2. 1. Afzali B
   2. Mitchell PJ
   3. Edozie FC
   4. Povoleri GA
   5. Dowson SE
   6. Demandt L
   7. Walter G
   8. Canavan JB
   9. Scotta C
   10. Menon B
   11. Chana PS
   12. Khamri W
   13. Kordasti SY
   14. Heck S
   15. Grimbacher B
   16. Tree T
   17. Cope AP
   18. Taams LS
   19. Lechler RI
   20. John S
   21. Lombardi G

   (2013) CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner

   European Journal of Immunology 43:2043–2054.

   https://doi.org/10.1002/eji.201243296

   • PubMed
   • Google Scholar
3. 1. Aramburu J
   2. Garcia-Cózar F
   3. Raghavan A
   4. Okamura H
   5. Rao A
   6. Hogan PG

   (1998) Selective inhibition of NFAT activation by a peptide spanning the calcineurin targeting site of NFAT

   Molecular Cell 1:627–637.

   https://doi.org/10.1016/S1097-2765(00)80063-5

   • PubMed
   • Google Scholar
4. 1. Aramburu J
   2. Yaffe MB
   3. López-Rodríguez C
   4. Cantley LC
   5. Hogan PG
   6. Rao A

   (1999) Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A

   Science 285:2129–2133.

   https://doi.org/10.1126/science.285.5436.2129

   • PubMed
   • Google Scholar
5. 1. Bandukwala HS
   2. Wu Y
   3. Feuerer M
   4. Chen Y
   5. Barboza B
   6. Ghosh S
   7. Stroud JC
   8. Benoist C
   9. Mathis D
   10. Rao A
   11. Chen L

   (2011) Structure of a domain-swapped FOXP3 dimer on DNA and its function in regulatory T cells

   Immunity 34:479–491.

   https://doi.org/10.1016/j.immuni.2011.02.017

   • PubMed
   • Google Scholar
6. 1. Basdeo SA
   2. Cluxton D
   3. Sulaimani J
   4. Moran B
   5. Canavan M
   6. Orr C
   7. Veale DJ
   8. Fearon U
   9. Fletcher JM

   (2017) Ex-Th17 (Nonclassical Th1) Cells are functionally distinct from classical Th1 and Th17 cells and are not constrained by regulatory T cells

   The Journal of Immunology 198:2249–2259.

   https://doi.org/10.4049/jimmunol.1600737

   • PubMed
   • Google Scholar
7. 1. Basu R
   2. Whitley SK
   3. Bhaumik S
   4. Zindl CL
   5. Schoeb TR
   6. Benveniste EN
   7. Pear WS
   8. Hatton RD
   9. Weaver CT

   (2015) IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the TH17 cell-iTreg cell balance

   Nature Immunology 16:286–295.

   https://doi.org/10.1038/ni.3099

   • PubMed
   • Google Scholar
8. 1. Brignall R
   2. Cauchy P
   3. Bevington SL
   4. Gorman B
   5. Pisco AO
   6. Bagnall J
   7. Boddington C
   8. Rowe W
   9. England H
   10. Rich K
   11. Schmidt L
   12. Dyer NP
   13. Travis MA
   14. Ott S
   15. Jackson DA
   16. Cockerill PN
   17. Paszek P

   (2017) Integration of kinase and calcium signaling at the level of chromatin underlies inducible gene activation in T cells

   The Journal of Immunology 199:2652–2667.

   https://doi.org/10.4049/jimmunol.1602033

   • PubMed
   • Google Scholar
9. 1. Chung Y
   2. Chang SH
   3. Martinez GJ
   4. Yang XO
   5. Nurieva R
   6. Kang HS
   7. Ma L
   8. Watowich SS
   9. Jetten AM
   10. Tian Q
   11. Dong C

   (2009) Critical regulation of early Th17 cell differentiation by interleukin-1 signaling

   Immunity 30:576–587.

   https://doi.org/10.1016/j.immuni.2009.02.007

   • PubMed
   • Google Scholar
10. 1. Colotta F
    2. Re F
    3. Muzio M
    4. Bertini R
    5. Polentarutti N
    6. Sironi M
    7. Giri JG
    8. Dower SK
    9. Sims JE
    10. Mantovani A

    (1993) Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4

    Science 261:472–475.

    https://doi.org/10.1126/science.8332913

    • PubMed
    • Google Scholar
11. 1. Colotta F
    2. Saccani S
    3. Giri JG
    4. Dower SK
    5. Sims JE
    6. Introna M
    7. Mantovani A

    (1996)

    Regulated expression and release of the IL-1 decoy receptor in human mononuclear phagocytes

    Journal of Immunology 156:2534–2541.

    • PubMed
    • Google Scholar
12. 1. Dinarello CA

    (2011) A clinical perspective of IL-1β as the gatekeeper of inflammation

    European Journal of Immunology 41:1203–1217.

    https://doi.org/10.1002/eji.201141550

    • PubMed
    • Google Scholar
13. 1. Dinarello CA
    2. Simon A
    3. van der Meer JW

    (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

    Nature Reviews Drug Discovery 11:633–652.

    https://doi.org/10.1038/nrd3800

    • PubMed
    • Google Scholar
14. 1. Downs-Canner S
    2. Berkey S
    3. Delgoffe GM
    4. Edwards RP
    5. Curiel T
    6. Odunsi K
    7. Bartlett DL
    8. Obermajer N

    (2017) Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ treg cells are a source of tumour-associated treg cells

    Nature Communications 8:14649.

    https://doi.org/10.1038/ncomms14649

    • Google Scholar
15. 1. Du R
    2. Zhao H
    3. Yan F
    4. Li H

    (2014) IL-17⁺Foxp3⁺ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells

    Journal of Leukocyte Biology 96:39–48.

    https://doi.org/10.1189/jlb.1RU0114-010RR

    • PubMed
    • Google Scholar
16. 1. Gaffen SL

    (2009) Structure and signalling in the IL-17 receptor family

    Nature Reviews Immunology 9:556–567.

    https://doi.org/10.1038/nri2586

    • Google Scholar
17. 1. Gagliani N
    2. Amezcua Vesely MC
    3. Iseppon A
    4. Brockmann L
    5. Xu H
    6. Palm NW
    7. de Zoete MR
    8. Licona-Limón P
    9. Paiva RS
    10. Ching T
    11. Weaver C
    12. Zi X
    13. Pan X
    14. Fan R
    15. Garmire LX
    16. Cotton MJ
    17. Drier Y
    18. Bernstein B
    19. Geginat J
    20. Stockinger B
    21. Esplugues E
    22. Huber S
    23. Flavell RA

    (2015) Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation

    Nature 523:221–225.

    https://doi.org/10.1038/nature14452

    • PubMed
    • Google Scholar
18. 1. Garlanda C
    2. Dinarello CA
    3. Mantovani A

    (2013a) The Interleukin-1 family: back to the future

    Immunity 39:1003–1018.

    https://doi.org/10.1016/j.immuni.2013.11.010

    • Google Scholar
19. 1. Garlanda C
    2. Riva F
    3. Bonavita E
    4. Gentile S
    5. Mantovani A

    (2013b) Decoys and regulatory "Receptors" of the IL-1/Toll-Like Receptor Superfamily

    Frontiers in Immunology 4:180.

    https://doi.org/10.3389/fimmu.2013.00180

    • PubMed
    • Google Scholar
20. 1. Hermann-Kleiter N
    2. Baier G

    (2010) NFAT pulls the strings during CD4+ T helper cell effector functions

    Blood 115:2989–2997.

    https://doi.org/10.1182/blood-2009-10-233585

    • PubMed
    • Google Scholar
21. 1. Hirota K
    2. Duarte JH
    3. Veldhoen M
    4. Hornsby E
    5. Li Y
    6. Cua DJ
    7. Ahlfors H
    8. Wilhelm C
    9. Tolaini M
    10. Menzel U
    11. Garefalaki A
    12. Potocnik AJ
    13. Stockinger B

    (2011) Fate mapping of IL-17-producing T cells in inflammatory responses

    Nature Immunology 12:255–263.

    https://doi.org/10.1038/ni.1993

    • PubMed
    • Google Scholar
22. 1. Hu H
    2. Djuretic I
    3. Sundrud MS
    4. Rao A

    (2007) Transcriptional partners in regulatory T cells: foxp3, runx and NFAT

    Trends in Immunology 28:329–332.

    https://doi.org/10.1016/j.it.2007.06.006

    • PubMed
    • Google Scholar
23. 1. Ichiyama K
    2. Gonzalez-Martin A
    3. Kim BS
    4. Jin HY
    5. Jin W
    6. Xu W
    7. Sabouri-Ghomi M
    8. Xu S
    9. Zheng P
    10. Xiao C
    11. Dong C

    (2016) The MicroRNA-183-96-182 cluster promotes T helper 17 cell pathogenicity by negatively regulating transcription factor Foxo1 expression

    Immunity 44:1284–1298.

    https://doi.org/10.1016/j.immuni.2016.05.015

    • PubMed
    • Google Scholar
24. 1. Jung MK
    2. Kwak JE
    3. Shin EC

    (2017) IL-17A-Producing Foxp3⁺regulatory T cells and human diseases

    Immune Network 17:276–286.

    https://doi.org/10.4110/in.2017.17.5.276

    • PubMed
    • Google Scholar
25. 1. Kang SW
    2. Kim SH
    3. Lee N
    4. Lee WW
    5. Hwang KA
    6. Shin MS
    7. Lee SH
    8. Kim WU
    9. Kang I

    (2012) 1,25-Dihyroxyvitamin D3 promotes FOXP3 expression via binding to vitamin D response elements in its conserved noncoding sequence region

    Journal of Immunology 188:5276–5282.

    https://doi.org/10.4049/jimmunol.1101211

    • PubMed
    • Google Scholar
26. 1. Kay J
    2. Calabrese L

    (2004) The role of interleukin-1 in the pathogenesis of rheumatoid arthritis

    Rheumatology 43 Suppl 3:iii2–iii9.

    https://doi.org/10.1093/rheumatology/keh201

    • PubMed
    • Google Scholar
27. 1. Kiani A
    2. Rao A
    3. Aramburu J

    (2000) Manipulating immune responses with immunosuppressive agents that target NFAT

    Immunity 12:359–372.

    https://doi.org/10.1016/S1074-7613(00)80188-0

    • PubMed
    • Google Scholar
28. 1. Kim BH
    2. Yoon BR
    3. Kim EK
    4. Noh KH
    5. Kwon SH
    6. Yi EH
    7. Lee HG
    8. Choi JS
    9. Kang SW
    10. Park IC
    11. Lee WW
    12. Ye SK

    (2016) Alleviation of collagen-induced arthritis by the benzoxathiole derivative BOT-4-one in mice: implication of the Th1- and Th17-cell-mediated immune responses

    Biochemical Pharmacology 110-111:47–57.

    https://doi.org/10.1016/j.bcp.2016.03.018

    • PubMed
    • Google Scholar
29. 1. Komatsu N
    2. Okamoto K
    3. Sawa S
    4. Nakashima T
    5. Oh-hora M
    6. Kodama T
    7. Tanaka S
    8. Bluestone JA
    9. Takayanagi H

    (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis

    Nature Medicine 20:62–68.

    https://doi.org/10.1038/nm.3432

    • Google Scholar
30. 1. Krummey SM
    2. Floyd TL
    3. Liu D
    4. Wagener ME
    5. Song M
    6. Ford ML

    (2014) Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade

    The Journal of Immunology 192:2495–2504.

    https://doi.org/10.4049/jimmunol.1301332

    • PubMed
    • Google Scholar
31. 1. Lee WW
    2. Kang SW
    3. Choi J
    4. Lee SH
    5. Shah K
    6. Eynon EE
    7. Flavell RA
    8. Kang I

    (2010) Regulating human Th17 cells via differential expression of IL-1 receptor

    Blood 115:530–540.

    https://doi.org/10.1182/blood-2009-08-236521

    • PubMed
    • Google Scholar
32. 1. Lee Y
    2. Awasthi A
    3. Yosef N
    4. Quintana FJ
    5. Xiao S
    6. Peters A
    7. Wu C
    8. Kleinewietfeld M
    9. Kunder S
    10. Hafler DA
    11. Sobel RA
    12. Regev A
    13. Kuchroo VK

    (2012) Induction and molecular signature of pathogenic TH17 cells

    Nature Immunology 13:991–999.

    https://doi.org/10.1038/ni.2416

    • Google Scholar
33. 1. Lee HG
    2. Kim LK
    3. Choi JM

    (2019) NFAT-specific inhibition by dNP2-VIVIT ameliorates autoimmune encephalomyelitis by regulation of Th1 and Th17

    Molecular Therapy - Methods & Clinical Development 16:32–41.

    https://doi.org/10.1016/j.omtm.2019.10.006

    • PubMed
    • Google Scholar
34. 1. Lee SH
    2. Soh H
    3. Chung JH
    4. Cho EH
    5. Lee SJ
    6. Ju JM
    7. Sheen JH
    8. Kim H
    9. Oh SJ
    10. Lee SJ
    11. Chung J
    12. Choi K
    13. Kim SY
    14. Ryu JS

    (2020) Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging

    PLOS ONE 15:e0223814.

    https://doi.org/10.1371/journal.pone.0223814

    • PubMed
    • Google Scholar
35. 1. Lim S
    2. Kim WJ
    3. Kim YH
    4. Lee S
    5. Koo JH
    6. Lee JA
    7. Yoon H
    8. Kim DH
    9. Park HJ
    10. Kim HM
    11. Lee HG
    12. Yun Kim J
    13. Lee JU
    14. Hun Shin J
    15. Kyun Kim L
    16. Doh J
    17. Kim H
    18. Lee SK
    19. Bothwell ALM
    20. Suh M
    21. Choi JM

    (2015) dNP2 is a blood-brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis

    Nature Communications 6:8244.

    https://doi.org/10.1038/ncomms9244

    • PubMed
    • Google Scholar
36. 1. Lozano T
    2. Villanueva L
    3. Durántez M
    4. Gorraiz M
    5. Ruiz M
    6. Belsúe V
    7. Riezu-Boj JI
    8. Hervás-Stubbs S
    9. Oyarzábal J
    10. Bandukwala H
    11. Lourenço AR
    12. Coffer PJ
    13. Sarobe P
    14. Prieto J
    15. Casares N
    16. Lasarte JJ

    (2015) Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    The Journal of Immunology 195:3180–3189.

    https://doi.org/10.4049/jimmunol.1402997

    • PubMed
    • Google Scholar
37. 1. Martin P
    2. Palmer G
    3. Rodriguez E
    4. Seemayer CA
    5. Palomo J
    6. Talabot-Ayer D
    7. Gabay C

    (2017) Deficiency in IL-1 receptor type 2 aggravates K/BxN serum Transfer-Induced arthritis in mice but has no impact on systemic inflammatory responses

    The Journal of Immunology 198:2916–2926.

    https://doi.org/10.4049/jimmunol.1600855

    • PubMed
    • Google Scholar
38. 1. McInnes IB
    2. O'Dell JR

    (2010) State-of-the-art: rheumatoid arthritis

    Annals of the Rheumatic Diseases 69:1898–1906.

    https://doi.org/10.1136/ard.2010.134684

    • PubMed
    • Google Scholar
39. 1. McInnes IB
    2. Schett G

    (2011) The pathogenesis of rheumatoid arthritis

    New England Journal of Medicine 365:2205–2219.

    https://doi.org/10.1056/NEJMra1004965

    • Google Scholar
40. 1. McMahan CJ
    2. Slack JL
    3. Mosley B
    4. Cosman D
    5. Lupton SD
    6. Brunton LL
    7. Grubin CE
    8. Wignall JM
    9. Jenkins NA
    10. Brannan CI

    (1991) A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types

    The EMBO Journal 10:2821–2832.

    https://doi.org/10.1002/j.1460-2075.1991.tb07831.x

    • PubMed
    • Google Scholar
41. 1. Mercer F
    2. Kozhaya L
    3. Unutmaz D

    (2010) Expression and function of TNF and IL-1 receptors on human regulatory T cells

    PLOS ONE 5:e8639.

    https://doi.org/10.1371/journal.pone.0008639

    • PubMed
    • Google Scholar
42. 1. Messeguer X
    2. Escudero R
    3. Farre D
    4. Nunez O
    5. Martinez J
    6. Alba MM

    (2002) PROMO: detection of known transcription regulatory elements using species-tailored searches

    Bioinformatics 18:333–334.

    https://doi.org/10.1093/bioinformatics/18.2.333

    • Google Scholar
43. 1. Miyara M
    2. Yoshioka Y
    3. Kitoh A
    4. Shima T
    5. Wing K
    6. Niwa A
    7. Parizot C
    8. Taflin C
    9. Heike T
    10. Valeyre D
    11. Mathian A
    12. Nakahata T
    13. Yamaguchi T
    14. Nomura T
    15. Ono M
    16. Amoura Z
    17. Gorochov G
    18. Sakaguchi S

    (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor

    Immunity 30:899–911.

    https://doi.org/10.1016/j.immuni.2009.03.019

    • PubMed
    • Google Scholar
44. 1. Neumann D
    2. Kollewe C
    3. Martin MU
    4. Boraschi D

    (2000) The membrane form of the type II IL-1 receptor accounts for inhibitory function

    The Journal of Immunology 165:3350–3357.

    https://doi.org/10.4049/jimmunol.165.6.3350

    • PubMed
    • Google Scholar
45. 1. Nie H
    2. Zheng Y
    3. Li R
    4. Guo TB
    5. He D
    6. Fang L
    7. Liu X
    8. Xiao L
    9. Chen X
    10. Wan B
    11. Chin YE
    12. Zhang JZ

    (2013) Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis

    Nature Medicine 19:322–328.

    https://doi.org/10.1038/nm.3085

    • PubMed
    • Google Scholar
46. 1. Niu Q
    2. Cai B
    3. Huang Z
    4. Shi Y
    5. Wang L

    (2012) Disturbed Th17/Treg balance in patients with rheumatoid arthritis

    Rheumatology International 32:2731–2736.

    https://doi.org/10.1007/s00296-011-1984-x

    • Google Scholar
47. 1. Noack M
    2. Miossec P

    (2014) Th17 and regulatory T cell balance in autoimmune and inflammatory diseases

    Autoimmunity Reviews 13:668–677.

    https://doi.org/10.1016/j.autrev.2013.12.004

    • Google Scholar
48. 1. Obermajer N
    2. Popp FC
    3. Soeder Y
    4. Haarer J
    5. Geissler EK
    6. Schlitt HJ
    7. Dahlke MH

    (2014) Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy

    The Journal of Immunology 193:4988–4999.

    https://doi.org/10.4049/jimmunol.1401776

    • PubMed
    • Google Scholar
49. 1. Purvis HA
    2. Stoop JN
    3. Mann J
    4. Woods S
    5. Kozijn AE
    6. Hambleton S
    7. Robinson JH
    8. Isaacs JD
    9. Anderson AE
    10. Hilkens CM

    (2010) Low-strength T-cell activation promotes Th17 responses

    Blood 116:4829–4837.

    https://doi.org/10.1182/blood-2010-03-272153

    • PubMed
    • Google Scholar
50. 1. Ritvo PG
    2. Churlaud G
    3. Quiniou V
    4. Florez L
    5. Brimaud F
    6. Fourcade G
    7. Mariotti-Ferrandiz E
    8. Klatzmann D

    (2017) T_fr cells lack IL-2Rα but express decoy IL-1R2 and IL-1Ra and suppress the IL-1-dependent activation of T_fh cells

    Science Immunology 2:eaan0368.

    https://doi.org/10.1126/sciimmunol.aan0368

    • PubMed
    • Google Scholar
51. 1. Ronchi F
    2. Basso C
    3. Preite S
    4. Reboldi A
    5. Baumjohann D
    6. Perlini L
    7. Lanzavecchia A
    8. Sallusto F

    (2016) Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells

    Nature Communications 7:11541.

    https://doi.org/10.1038/ncomms11541

    • PubMed
    • Google Scholar
52. 1. Rudra D
    2. deRoos P
    3. Chaudhry A
    4. Niec RE
    5. Arvey A
    6. Samstein RM
    7. Leslie C
    8. Shaffer SA
    9. Goodlett DR
    10. Rudensky AY

    (2012) Transcription factor Foxp3 and its protein partners form a complex regulatory network

    Nature Immunology 13:1010–1019.

    https://doi.org/10.1038/ni.2402

    • PubMed
    • Google Scholar
53. 1. Schlüter T
    2. Schelmbauer C
    3. Karram K
    4. Mufazalov IA

    (2018) Regulation of IL-1 signaling by the decoy receptor IL-1R2

    Journal of Molecular Medicine 96:983–992.

    https://doi.org/10.1007/s00109-018-1684-z

    • PubMed
    • Google Scholar
54. 1. Shimizu K
    2. Nakajima A
    3. Sudo K
    4. Liu Y
    5. Mizoroki A
    6. Ikarashi T
    7. Horai R
    8. Kakuta S
    9. Watanabe T
    10. Iwakura Y

    (2015) IL-1 receptor type 2 suppresses collagen-induced arthritis by inhibiting IL-1 signal on macrophages

    The Journal of Immunology 194:3156–3168.

    https://doi.org/10.4049/jimmunol.1402155

    • PubMed
    • Google Scholar
55. 1. Shirakawa F
    2. Tanaka Y
    3. Ota T
    4. Suzuki H
    5. Eto S
    6. Yamashita U

    (1987)

    Expression of interleukin 1 receptors on human peripheral T cells

    Journal of Immunology 138:4243–4248.

    • PubMed
    • Google Scholar
56. 1. Stadhouders R
    2. Lubberts E
    3. Hendriks RW

    (2018) A cellular and molecular view of T helper 17 cell plasticity in autoimmunity

    Journal of Autoimmunity 87:1–15.

    https://doi.org/10.1016/j.jaut.2017.12.007

    • Google Scholar
57. 1. Stockinger B
    2. Omenetti S

    (2017) The dichotomous nature of T helper 17 cells

    Nature Reviews Immunology 17:535–544.

    https://doi.org/10.1038/nri.2017.50

    • Google Scholar
58. 1. Sutton C
    2. Brereton C
    3. Keogh B
    4. Mills KHG
    5. Lavelle EC

    (2006) A crucial role for interleukin (IL)-1 in the induction of IL-17–producing T cells that mediate autoimmune encephalomyelitis

    Journal of Experimental Medicine 203:1685–1691.

    https://doi.org/10.1084/jem.20060285

    • Google Scholar
59. 1. Tabarkiewicz J
    2. Pogoda K
    3. Karczmarczyk A
    4. Pozarowski P
    5. Giannopoulos K

    (2015) The role of IL-17 and Th17 lymphocytes in autoimmune diseases

    Archivum Immunologiae Et Therapiae Experimentalis 63:435–449.

    https://doi.org/10.1007/s00005-015-0344-z

    • PubMed
    • Google Scholar
60. 1. Thibaudin M
    2. Chaix M
    3. Boidot R
    4. Végran F
    5. Derangère V
    6. Limagne E
    7. Berger H
    8. Ladoire S
    9. Apetoh L
    10. Ghiringhelli F

    (2016) Human ectonucleotidase-expressing CD25 ^high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions

    OncoImmunology 5:e1055444.

    https://doi.org/10.1080/2162402X.2015.1055444

    • Google Scholar
61. 1. Tran DQ
    2. Andersson J
    3. Hardwick D
    4. Bebris L
    5. Illei GG
    6. Shevach EM

    (2009) Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures

    Blood 113:5125–5133.

    https://doi.org/10.1182/blood-2009-01-199950

    • Google Scholar
62. 1. Wang W
    2. Shao S
    3. Jiao Z
    4. Guo M
    5. Xu H
    6. Wang S

    (2012) The Th17/Treg imbalance and cytokine environment in peripheral blood of patients with rheumatoid arthritis

    Rheumatology International 32:887–893.

    https://doi.org/10.1007/s00296-010-1710-0

    • Google Scholar
63. 1. Wang C
    2. Yosef N
    3. Gaublomme J
    4. Wu C
    5. Lee Y
    6. Clish CB
    7. Kaminski J
    8. Xiao S
    9. Meyer Zu Horste G
    10. Pawlak M
    11. Kishi Y
    12. Joller N
    13. Karwacz K
    14. Zhu C
    15. Ordovas-Montanes M
    16. Madi A
    17. Wortman I
    18. Miyazaki T
    19. Sobel RA
    20. Park H
    21. Regev A
    22. Kuchroo VK

    (2015) CD5L/AIM regulates lipid biosynthesis and restrains Th17 cell pathogenicity

    Cell 163:1413–1427.

    https://doi.org/10.1016/j.cell.2015.10.068

    • PubMed
    • Google Scholar
64. 1. Wilson NJ
    2. Boniface K
    3. Chan JR
    4. McKenzie BS
    5. Blumenschein WM
    6. Mattson JD
    7. Basham B
    8. Smith K
    9. Chen T
    10. Morel F
    11. Lecron JC
    12. Kastelein RA
    13. Cua DJ
    14. McClanahan TK
    15. Bowman EP
    16. de Waal Malefyt R

    (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells

    Nature Immunology 8:950–957.

    https://doi.org/10.1038/ni1497

    • PubMed
    • Google Scholar
65. 1. Wu Y
    2. Borde M
    3. Heissmeyer V
    4. Feuerer M
    5. Lapan AD
    6. Stroud JC
    7. Bates DL
    8. Guo L
    9. Han A
    10. Ziegler SF
    11. Mathis D
    12. Benoist C
    13. Chen L
    14. Rao A

    (2006) FOXP3 controls regulatory T cell function through cooperation with NFAT

    Cell 126:375–387.

    https://doi.org/10.1016/j.cell.2006.05.042

    • PubMed
    • Google Scholar
66. 1. Zhang Y
    2. Maksimovic J
    3. Naselli G
    4. Qian J
    5. Chopin M
    6. Blewitt ME
    7. Oshlack A
    8. Harrison LC

    (2013) Genome-wide DNA methylation analysis identifies hypomethylated genes regulated by FOXP3 in human regulatory T cells

    Blood 122:2823–2836.

    https://doi.org/10.1182/blood-2013-02-481788

    • Google Scholar
67. 1. Zheng Y
    2. Humphry M
    3. Maguire JJ
    4. Bennett MR
    5. Clarke MC

    (2013) Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation

    Immunity 38:285–295.

    https://doi.org/10.1016/j.immuni.2013.01.008

    • PubMed
    • Google Scholar
68. 1. Zhou L
    2. Lopes JE
    3. Chong MM
    4. Ivanov II
    5. Min R
    6. Victora GD
    7. Shen Y
    8. Du J
    9. Rubtsov YP
    10. Rudensky AY
    11. Ziegler SF
    12. Littman DR

    (2008) TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function

    Nature 453:236–240.

    https://doi.org/10.1038/nature06878

    • PubMed
    • Google Scholar
69. 1. Zielinski CE
    2. Mele F
    3. Aschenbrenner D
    4. Jarrossay D
    5. Ronchi F
    6. Gattorno M
    7. Monticelli S
    8. Lanzavecchia A
    9. Sallusto F

    (2012) Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β

    Nature 484:514–518.

    https://doi.org/10.1038/nature10957

    • PubMed
    • Google Scholar

Author details

1. Dong Hyun Kim

   Laboratory of Autoimmunity and Inflammation (LAI), Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea

   Contribution

   Data curation, Software, Formal analysis, Investigation, Writing - original draft

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-2765-4376

2. Hee Young Kim

   1. Laboratory of Autoimmunity and Inflammation (LAI), Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
   2. Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea
   3. Cancer Research Institute and Institute of Infectious Diseases, Seoul National University College of Medicine, Seoul, Republic of Korea

   Contribution

   Data curation, Formal analysis, Investigation, Methodology

   Competing interests

   No competing interests declared

3. Sunjung Cho

   Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea

   Contribution

   Data curation, Formal analysis, Investigation, Methodology

   Competing interests

   No competing interests declared

4. Su-Jin Yoo

   Department of Internal Medicine, Chungnam National University School of Medicine, 282 Munhwa-ro, Jung-gu, Daejeon, Republic of Korea

   Contribution

   Resources, Formal analysis, Investigation

   Competing interests

   No competing interests declared

5. Won-Ju Kim

   Department of Life Science, College of Natural Sciences and Research Institute for Natural Sciences, Hanyang University, Seoul, Republic of Korea

   Contribution

   Formal analysis, Investigation, Methodology

   Competing interests

   No competing interests declared

6. Hye Ran Yeon

   Department of Biochemistry and Molecular Biology, Department of Biomedical Sciences, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

   Contribution

   Resources, Investigation, Methodology

   Competing interests

   No competing interests declared

7. Kyungho Choi

   Department of Biochemistry and Molecular Biology, Department of Biomedical Sciences, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea

   Contribution

   Conceptualization, Resources, Formal analysis, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

8. Je-Min Choi

   Department of Life Science, College of Natural Sciences and Research Institute for Natural Sciences, Hanyang University, Seoul, Republic of Korea

   Contribution

   Conceptualization, Investigation, Methodology, Writing - review and editing

   Competing interests

   No competing interests declared

9. Seong Wook Kang

   Department of Internal Medicine, Chungnam National University School of Medicine, 282 Munhwa-ro, Jung-gu, Daejeon, Republic of Korea

   Contribution

   Conceptualization, Resources, Data curation, Investigation

   Competing interests

   No competing interests declared

10. Won-Woo Lee

    1. Laboratory of Autoimmunity and Inflammation (LAI), Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
    2. Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea
    3. Cancer Research Institute and Institute of Infectious Diseases, Seoul National University College of Medicine, Seoul, Republic of Korea
    4. Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine; Seoul National University Hospital Biomedical Research Institute, Seoul, Republic of Korea

    Contribution

    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Writing - original draft, Project administration, Writing - review and editing

    For correspondence

    wonwoolee@snu.ac.kr

    Competing interests

    No competing interests declared

    "This ORCID iD identifies the author of this article:" 0000-0002-5347-9591

• 1,369

  views

• 241

  downloads

• 8

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.